A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
NCT05277493 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2022-04-27
Summary
The purpose of this protocol is to generate a registry of Chinese patients with AL amyloidosis treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy.
Conditions
- AL Amyloidosis
Sponsors & Collaborators
-
Peking Union Medical College Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-30
- Primary Completion
- 2025-03-31
- Completion
- 2025-09-30
Countries
- China
Study Locations
More Related Trials
-
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
NCT07079423 ·Status: RECRUITING ·Phase: PHASE2
-
Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis
NCT04943302 ·Status: WITHDRAWN ·Phase: PHASE2
-
Research of SORD-CMT Natural History and Epalrestat Treatment
NCT05777226 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
AL Amyloidosis and Anti-CD38-Daratunumab
NCT06571864 ·Status: COMPLETED ·Phase: NA
-
Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis
NCT02816476 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832 ·Status: RECRUITING
-
Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
NCT07039578 ·Status: RECRUITING ·Phase: PHASE2
-
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
NCT04535843 ·Status: RECRUITING
-
A Registered Cohort Study of Immune-Mediated Neuropathies
NCT04292834 ·Status: UNKNOWN
-
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
NCT05775042 ·Status: RECRUITING ·Phase: PHASE2
-
Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis
NCT04316442 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
NCT00079768 ·Status: COMPLETED ·Phase: PHASE2
-
A Real World Study About PMN
NCT06893328 ·Status: RECRUITING
-
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
NCT05332587 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
NCT06158854 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
NCT00002849 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A
NCT05092841 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Myasthenic Crisis in China
NCT04837625 ·Status: RECRUITING
-
A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants
NCT04085289 ·Status: COMPLETED ·Phase: PHASE1
-
Canakinumab for Treatment of Adult-onset Still's Disease
NCT02204293 ·Status: TERMINATED ·Phase: PHASE2
-
Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
NCT00487708 ·Status: COMPLETED ·Phase: PHASE2
-
IC14 for Treatment of Amyotrophic Lateral Sclerosis
NCT03508453 ·Status: WITHDRAWN ·Phase: PHASE2
-
Screening to Improve Survival in AL Amyloidosis
NCT04615572 ·Status: COMPLETED
-
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
NCT05039190 ·Status: COMPLETED ·Phase: PHASE3
-
A Study in Patients With Myasthenia Gravis in China
NCT06700616 ·Status: ACTIVE_NOT_RECRUITING